Innoventric

Company Overview

Snapshot

Founded in February 2016 by Amir Danino, David Planer, and Rafi Benary, Innoventric operates with 11–50 employees. The company has raised $42.5M across 4 funding rounds from 6 investors. In October 2024, Innoventric secured a B Round of funding, with RA Capital Management participating as a lead investor.

Business overview

Innoventric is a structural heart medical device company focused on developing percutaneous solutions for tricuspid regurgitation and right heart disease. Its core product, Trillium, is an easily deployable percutaneous functional tricuspid valve replacement that uses cross-caval anchoring and an innovative multi-valve design for long-lasting blood flow regulation. The company aims to significantly improve the quality of life and lifespan for patients with structural heart disease, serving the healthcare provider market within the Health Tech & Life Sciences sector.

Strategic signal

In October 2024, Innoventric secured $28.5M in funding, which is intended to reduce the medical need for surgical valve replacement and general anesthesia. This investment signals strong investor confidence in Innoventric's innovative transcatheter solutions and their potential to transform treatment paradigms for tricuspid regurgitation, indicating a positive trajectory for market adoption and clinical impact.

Company Intelligence Q&A

What significant funding did Innoventric receive in October 2024?

In October 2024, Innoventric secured $28.5M in a B Round of funding. RA Capital Management was a lead investor in this round.

What was a key strategic development for Innoventric in November 2021?

In November 2021, Innoventric won the prestigious Horizon Europe Grant and secured a Series A investment. Investors in this round included JG Investment and BRM Group.

Who are the founders of Innoventric?

Innoventric was co-founded by Amir Danino, David Planer, and Rafi Benary.

What is Innoventric's primary product?

Innoventric's primary product is Trillium, a percutaneous functional tricuspid valve replacement designed for long-lasting blood flow regulation.

What is the total capital raised by Innoventric?

Innoventric has raised a total of $42.5M across 4 funding rounds.